These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32663067)

  • 21. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
    Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn AM; Lowry S; Feldman S; Wu JJ; Armstrong AW
    J Dermatolog Treat; 2022 Mar; 33(2):740-748. PubMed ID: 32602762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
    Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
    BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
    Yang J; Wang Z; Zhang X
    J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
    Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
    J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
    Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
    J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    Puig L; Notario J; Jiménez-Morales A; Moreno-Ramírez D; López-Ferrer A; Gozalbo I; Prades M; Lizán L; Blanch C
    J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
    Li N; Teeple A; Muser E; You Y; Song M; Armstrong AW
    J Dermatolog Treat; 2022 Feb; 33(1):278-283. PubMed ID: 32233940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
    Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
    Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.